Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.

Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF.

J Clin Oncol. 2011 Oct 20;29(30):3960-7. doi: 10.1200/JCO.2011.37.1021. Epub 2011 Sep 12. Erratum in: J Clin Oncol. 2011 Dec 1;29(34):4596-8.

2.

Transarterial chemoembolization with Doxorubicin-eluting microspheres for inoperable hepatocellular carcinoma.

Kalva SP, Iqbal SI, Yeddula K, Blaszkowsky LS, Akbar A, Wicky S, Zhu AX.

Gastrointest Cancer Res. 2011 Jan;4(1):2-8.

3.

Hepatic resection versus transarterial lipiodol chemoembolization as the initial treatment for large, multiple, and resectable hepatocellular carcinomas: a prospective nonrandomized analysis.

Luo J, Peng ZW, Guo RP, Zhang YQ, Li JQ, Chen MS, Shi M.

Radiology. 2011 Apr;259(1):286-95. doi: 10.1148/radiol.10101072. Epub 2011 Feb 17.

PMID:
21330557
4.

Novel intraarterial therapy for liver cancer using ethylbromopyruvate dissolved in an iodized oil.

Choi YH, Chung JW, Son KR, So YH, Kim W, Yoon CJ, Yoon JH, Chung H, Kim HC, Jae HJ, Kim YI, Park JH.

Acad Radiol. 2011 Apr;18(4):471-8. doi: 10.1016/j.acra.2010.12.001. Epub 2011 Jan 14.

PMID:
21237678
5.

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.

Salem R, Lewandowski RJ, Kulik L, Wang E, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Ibrahim SM, Senthilnathan S, Baker T, Gates VL, Atassi B, Newman S, Memon K, Chen R, Vogelzang RL, Nemcek AA, Resnick SA, Chrisman HB, Carr J, Omary RA, Abecassis M, Benson AB 3rd, Mulcahy MF.

Gastroenterology. 2011 Feb;140(2):497-507.e2. doi: 10.1053/j.gastro.2010.10.049. Epub 2010 Oct 30.

6.

Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.

Schwarz RE, Abou-Alfa GK, Geschwind JF, Krishnan S, Salem R, Venook AP; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract.

HPB (Oxford). 2010 Jun;12(5):313-20. doi: 10.1111/j.1477-2574.2010.00183.x.

7.

Surgical treatment of hepatocellular carcinoma: expert consensus statement.

Jarnagin W, Chapman WC, Curley S, D'Angelica M, Rosen C, Dixon E, Nagorney D; American Hepato-Pancreato-Biliary Association; Society of Surgical Oncology; Society for Surgery of the Alimentary Tract.

HPB (Oxford). 2010 Jun;12(5):302-10. doi: 10.1111/j.1477-2574.2010.00182.x. Review.

8.

Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria--selection parameter for liver transplantation.

Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, De Simone P, Filipponi F, Bartolozzi C.

Radiology. 2010 Apr;255(1):289-300. doi: 10.1148/radiol.09090927.

PMID:
20308465
9.

Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC).

Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS.

J Surg Oncol. 2010 May 1;101(6):476-80. doi: 10.1002/jso.21522.

PMID:
20213741
10.
11.

Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma.

Kooby DA, Egnatashvili V, Srinivasan S, Chamsuddin A, Delman KA, Kauh J, Staley CA 3rd, Kim HS.

J Vasc Interv Radiol. 2010 Feb;21(2):224-30. doi: 10.1016/j.jvir.2009.10.013. Epub 2009 Dec 21.

PMID:
20022765
12.

Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States.

Reyes DK, Vossen JA, Kamel IR, Azad NS, Wahlin TA, Torbenson MS, Choti MA, Geschwind JF.

Cancer J. 2009 Nov-Dec;15(6):526-32. doi: 10.1097/PPO.0b013e3181c5214b.

13.

Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up.

Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F.

Cardiovasc Intervent Radiol. 2010 Jun;33(3):552-9. doi: 10.1007/s00270-009-9752-y. Epub 2009 Dec 3.

PMID:
19957182
14.

Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study.

Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators.

Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52. doi: 10.1007/s00270-009-9711-7. Epub 2009 Nov 12.

15.

Interventional oncology: new options for interstitial treatments and intravascular approaches: targeting tumor metabolism via a loco-regional approach: a new therapy against liver cancer.

Liapi E, Geschwind JF.

J Hepatobiliary Pancreat Sci. 2010 Jul;17(4):405-6. doi: 10.1007/s00534-009-0236-x. Epub 2009 Nov 5. Review.

16.

Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes.

Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L.

Gastroenterology. 2010 Jan;138(1):52-64. doi: 10.1053/j.gastro.2009.09.006. Epub 2009 Sep 18.

PMID:
19766639
17.

An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data.

Pelletier SJ, Fu S, Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, Magee JC, Lok AS, Fontana RJ, Marrero JA.

Liver Transpl. 2009 Aug;15(8):859-68. doi: 10.1002/lt.21778.

18.

A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization.

Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK, Ibrahim SM, Sato KT, Baker T, Miller FH, Omary R, Abecassis M, Salem R.

Am J Transplant. 2009 Aug;9(8):1920-8. doi: 10.1111/j.1600-6143.2009.02695.x. Epub 2009 Jun 22.

19.

Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Altekruse SF, McGlynn KA, Reichman ME.

J Clin Oncol. 2009 Mar 20;27(9):1485-91. doi: 10.1200/JCO.2008.20.7753. Epub 2009 Feb 17.

20.

Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria.

Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, Vivarelli M, Golfieri R, D'Errico Grigioni A, Panzini I, Morelli C, Bernardi M, Bolondi L, Pinna AD.

Am J Transplant. 2008 Dec;8(12):2547-57. doi: 10.1111/j.1600-6143.2008.02409.x.

Supplemental Content

Support Center